Figure 2.
![Figure 2. KRN5500 induces caspase-3 activation and cleavage of PARP. (A) KRN5500 induces caspase-3 activation in human CLL cells in vitro. CLL cells were exposed to 24 hours of media (i) or KRN5500 (0.134 [ii] and 1.34 μM [iii]) and then examined for the presence of the active 29 kDa heterodimer of effector caspase-3. An increase in fluorescence is observed with KRN5500 exposure at 24 hours that is indicative of caspase-3 activation. (B) KRN5500 induces cleavage of PARP in human CLL cells in vitro. CLL cells were exposed to 24 hours of media or KRN5500 (0.134 and 1.34 μM) followed by immunoblotting for PARP. A dose-dependent increase in the cleaved p85 fragment of PARP is observed following 24 hours of exposure of KRN5500.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/101/11/10.1182_blood-2002-08-2623/5/h81134410002.jpeg?Expires=1724246803&Signature=M5WIZFpIA2zxqddkhCtv9aEr~~Qa-U4DR9V0iHADYoVykxM~gjbnRaxQWHtRgEWWhULK0hSJIThLLRBrr9HxspVivJu-WiYHcvA0uuiZbaKw86lnEmQl4V9S0HdX5NyuWJaSz1NhRUnPp-QVoq~lFyrjpGMKBkWn~IvIaLPYEbkH1vuAYNRXK8UCeAFl-m8WCY2Gb3CrPeue3hJZOnvEr~y7pz4eqOSlRrVFd~9Y-b-1qk5JBYao6lc-~yF8od6~~-eQaTggCvpTz4rCBltLVhUi-37riN3CcYQJyUejG3nBbXvr8fot1~UxBvJ1NxUcy4f7difz1TtPo3Pze95JKw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
KRN5500 induces caspase-3 activation and cleavage of PARP. (A) KRN5500 induces caspase-3 activation in human CLL cells in vitro. CLL cells were exposed to 24 hours of media (i) or KRN5500 (0.134 [ii] and 1.34 μM [iii]) and then examined for the presence of the active 29 kDa heterodimer of effector caspase-3. An increase in fluorescence is observed with KRN5500 exposure at 24 hours that is indicative of caspase-3 activation. (B) KRN5500 induces cleavage of PARP in human CLL cells in vitro. CLL cells were exposed to 24 hours of media or KRN5500 (0.134 and 1.34 μM) followed by immunoblotting for PARP. A dose-dependent increase in the cleaved p85 fragment of PARP is observed following 24 hours of exposure of KRN5500.
